临床决策支持系统对急性缺血性卒中患者卒中护理质量与结局的影响(GOLDEN BRIDGE II):整群随机临床试验
该多中心整群随机临床试验纳入中国77家医院(干预组38家、对照组39家)共21603例症状发作7天内入院的急性缺血性卒中患者。干预组医院接受卒中临床决策支持系统支持,包括人工智能辅助影像分析、卒中病因分型及循证治疗推荐;对照组提供常规诊疗。主要终点为初始症状发作后3个月内新发血管事件(缺血性卒中、出血性卒中、心肌梗死和血管性死亡的复合终点),干预组2.9%(320/11054)vs 对照组3.9%(416/10549),校正HR 0.74(95%CI 0.58-0.93,P=0.01)。干预组循证绩效指标复合达标率更高(91.4% vs 89.8%,校正OR 1.21,95%CI 1.17-1.26,P<0.001),12个月新发血管事件亦显著降低(4.0% vs 5.5%,校正HR 0.73,95%CI 0.56-0.95,P=0.02);残疾和全因死亡率无显著差异,出血事件无显著差异。
要点
- 中国77家医院整群随机试验:卒中CDSS使3个月新发血管事件从3.9%(416/10549)降至2.9%(320/11054),校正HR 0.74(95%CI 0.58-0.93,P=0.01)。
- CDSS组循证绩效指标复合达标率91.4%(77049/84276)vs 对照组89.8%(70794/78834),校正OR 1.21(95%CI 1.17-1.26,P<0.001)。
- 12个月新发血管事件CDSS组4.0%(440/11054)vs 对照组5.5%(576/10549),校正HR 0.73(95%CI 0.56-0.95,P=0.02)。
- 残疾(改良Rankin量表评分3-6)和全因死亡率在两组间无显著差异,中度或重度出血及所有出血事件亦无显著差异。
- CDSS支持内容包括人工智能辅助影像分析、卒中病因分型和循证治疗推荐,对照组为常规诊疗。
适用人群与场景
- 中国77家医院中症状发作7天内入院的急性缺血性卒中患者,共21603例(干预组11054例,对照组10549例)。
处置流程与药物剂量
- 干预组医院接受卒中临床决策支持系统支持,包括人工智能辅助影像分析、卒中病因分型及循证治疗推荐;对照组医院提供常规诊疗。
研究设计与关键结果
- 研究类型:多中心整群随机临床试验,中国77家医院(干预组38家、对照组39家),纳入21603例症状发作7天内入院的急性缺血性卒中患者;干预为卒中CDSS支持(人工智能辅助影像分析、卒中病因分型、循证治疗推荐),对照为常规诊疗。
- 主要终点:3个月新发血管事件(缺血性卒中、出血性卒中、心肌梗死和血管性死亡的复合终点)干预组2.9%(320/11054)vs 对照组3.9%(416/10549),校正HR 0.74(95%CI 0.58-0.93,P=0.01);整群水平分析干预效应仍显著(-0.01,95%CI -0.02至-0.004,P=0.003)。
- 关键次要终点:循证绩效指标复合达标率干预组91.4%(77049/84276)vs 对照组89.8%(70794/78834),校正OR 1.21(95%CI 1.17-1.26,P<0.001);12个月新发血管事件干预组4.0%(440/11054)vs 对照组5.5%(576/10549),校正HR 0.73(95%CI 0.56-0.95,P=0.02)。
- 残疾(改良Rankin量表评分3-6)和全因死亡率在3、6、12个月两组间无显著差异;中度或重度出血及所有出血事件在3、6、12个月两组间无显著差异。
证据类型、等级与局限
- 证据类型:多中心整群随机临床试验(ClinicalTrials.gov NCT04524624)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在中国急性缺血性卒中患者中,使用卒中CDSS可显著降低3个月新发血管事件,并改善卒中护理质量、降低长期血管事件;该干预对残疾和全因死亡率无显著影响,出血事件无显著增加。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To evaluate the efficacy of a clinical decision support system (CDSS) on stroke care quality and clinical outcomes among patients with acute ischaemic stroke.
DESIGN: Multicentre, cluster randomised clinical trial.
SETTING: 77 hospitals across China.
PARTICIPANTS: 77 hospitals (38 randomised to intervention group, 39 to control group) enrolled 21 603 patients with acute ischaemic stroke admitted to hospital within seven days after symptom onset.
INTERVENTIONS: Hospitals in the intervention group received stroke CDSS support including artificial intelligence assisted imaging analysis, classification of stroke causes, and evidence based treatment recommendations. Hospitals in the control group provided usual care.
MAIN OUTCOMES MEASURES: The primary outcome was a new vascular event (composite of ischaemic stroke, haemorrhagic stroke, myocardial infarction, and vascular death) within three months after initial symptom onset. Secondary outcomes included the composite measure and all-or-none measure of evidence based performance measures for acute ischaemic stroke care quality, a new vascular event at six and 12 months, and disability (modified Rankin Scale score 3-6) and all cause mortality at three, six, and 12 months. Safety outcomes were moderate or severe bleeding events and all bleeding events at three, six, and 12 months.
RESULTS: 11 054 patients in the intervention group and 10 549 patients in the control group were enrolled from January 2021 to June 2023. New vascular events at three months occurred in 2.9% (320/11 054) in the intervention group compared with 3.9% (416/10 549) in the control group (adjusted hazard ratio 0.74, 95% confidence interval (CI) 0.58 to 0.93, P=0.01). The CDSS intervention effect remained significant in the cluster level analysis (-0.01, -0.02 to -0.004, P=0.003). Patients in the intervention group were more likely to have a higher composite measure (91.4% (77 049/84 276) v 89.8% (70 794/78 834), adjusted odds ratio 1.21, 95% CI 1.17 to 1.26, P<0.001). New vascular events were significantly lower in the intervention group at 12 months (4.0% (440/11 054) v 5.5% (576/10 549), adjusted hazard ratio 0.73, 95% CI 0.56 to 0.95, P=0.02). No significant differences were found in disability and all cause mortality. Moderate or severe bleeding, and all bleeding did not differ significantly between the two groups.
CONCLUSIONS: Use of the stroke CDSS in patients with acute ischaemic stroke in China led to a significant decrease in new vascular events at three months. The stroke CDSS intervention was also effective in improving stroke care quality and decreasing long term vascular events.
TRIAL REGISTRATION: ClinicalTrials.gov NCT04524624.
参考来源
- Zhang X, Ding L, Jing J, et al. Effect of a clinical decision support system on stroke care quality and outcomes in patients with acute ischaemic stroke (GOLDEN BRIDGE II): cluster randomised clinical trial. BMJ. 2026. PMID: 41862204. doi:10.1136/bmj-2025-085810
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。